The LungVax vaccine uses technology similar to the Oxford/AstraZeneca COVID-19 vaccine. The team will receive funding for the study over the next 2 years. It will carry a strand of DNA which trains the immune system to recognize these neoantigens on abnormal lung cells. If this work is successful, the vaccine will move straight into a clinical trial.